Molecular diagnostics primarily refers to the class of diagnostic tests that identifies nucleic acids or proteins at the molecular level. Molecular diagnostics has emerged as one of the fastest growing segments in in vitro diagnostics industry. The market for has expanded rapidly since 1990’s with the introduction of PCR test for HIV and Chlamydia trachomatis and Neisseria gonorrhea (CT/NG). Since then, within a span of 20 years market has shown a significant growth. Currently, molecular diagnostics kits are being widely adopted for testing genetic diseases, cancer, hepatitis virus and hospital acquired infections. Likewise, molecular diagnostics kits are also being used extensively for blood donor screening test for hepatitis and HIV.
The molecular diagnostic tests uses a number of technologies such as polymerase chain reaction, hybridization (ISH AND FISH), mass spectrometry, transcription mediated amplification (TMA), next generation sequencing, biochips and microfluidics, others which includes nanotechnology and proteomics. The polymerase chain reaction dominated the market in Europe accounting for the share of 40.1% in 2014 as the technique is cost-effective way for copying or amplification of small segments of DNA or RNA. However, next generation sequencing segment is expected to register the fastest growth during the forecast period due to its high throughput, speed, flexibility which has ability to generate hundreds of gigabases of data in a single sequencing run.
Molecular diagnostic tests are used in various medical areas including oncology, infectious disease testing, genomics, blood screening, women's health, microbiology, and prenatal and newborn screening. Infectious disease testing held the largest market share of 30.6% in 2014 owing to increasing incidence of a number of chronic infectious diseases including tuberculosis, hepatitis, HIV and others in Europe. The oncology segment is projected to grow at the fastest CAGR within the application segment. The major factors driving the oncology segment are highly sensitive and specific cancer diagnostic protocol through molecular diagnostic tests. Furthermore, continuous rise in the incidence of cancer rate is also expected to boost the growth of oncology segment in Europe during the forecast period from 2015 to 2023.
The Europe molecular diagnostics market has been segmented into five major regions, namely, Northern Europe, Eastern Europe, Western Europe, Southern Europe, and Rest of Europe, which are further categorized into various countries under each region. Western Europe dominated the Europe molecular diagnostic market in 2014 with a share of 47.1% due to factors such as rising prevalence of infectious disorders, and increasing number of government initiatives. In addition, growing preference of the population to opt for affordable molecular diagnostic tests is another factor supporting the market growth in this region. Eastern Europe is projected to be the most lucrative market for Europe molecular diagnostic market and is expected to expand at the highest growth rate from 2015 to 2023. Factors propelling the growth of the Europe molecular diagnostic market are rising disposable income among population, and rising health care awareness among the people pertaining to molecular diagnostic tests.
F. Hoffmann-La Roche Ltd. dominated the Europe molecular diagnostic market in 2014. Major factors attributed to its dominance are broad product portfolio and widespread market presence. Abbott Laboratories secured the second market position offering a wide range of molecular diagnostic tests. Other players in the Europe molecular diagnostic market include QIAGEN N.V., Hologic, Inc., Cepheid, Inc., Siemens AG, Alere. Inc., BioMerieux, Bio-Rad Laboratories, PerkinElmer, Inc., Thermo Fisher Scientific, Inc., and others.
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
2. Executive Summary
2.1. Europe Molecular Diagnostics Market Revenue, 2013–2023 (US$ Mn)
2.2. Europe Market, by Technology, 2014 (US$ Mn)
2.3. Europe Market, by Application, 2014 (US$ Mn)
2.4. Europe Market Share by Major Region, 2014 and 2023 (Value %)
2.5. Europe Market Snapshot
3. Europe Molecular Diagnostics Market – Industry Analysis
3.2.1. Rising prevalence of chronic and infectious diseases in Europe
3.2.2. Increasing awareness and acceptance of companion diagnostics and personalized medicines
3.3.1. Issues with reimbursement policies
3.4.1. Technological advancement to offer sustained growth opportunities
3.5. Porter’s Five Forces Analysis: Europe Market
3.6. Market Attractiveness Analysis – Europe Market, By Region
3.7. Market Attractiveness Analysis – Europe Market, By Technology
3.8. Market Attractiveness Analysis – Europe Market, By Application
3.9. Patient Pool Analysis, by Infectious Diseases
3.10. Patient Pool Analysis, by Cancer
3.11. Patient Pool Analysis, by Cardiovascular Diseases
3.12. Company Market Share, Europe Molecular Diagnostics Market, By Key Players (2014) (%)
3.13. Competitive Landscape
3.13.1. ADL Matrix Analysis, 2014, by Top 3 Market Players
3.13.2. Brand Positioning Map, by Top 5 Market Players
3.13.3. Business Performance Analysis: F. Hoffmann-La Roche AG
3.13.4. Business Performance Analysis: Abbott Laboratories
3.13.5. Business Performance Analysis: QIAGEN
3.13.6. End-user Analysis (Growth Share Matrix)
3.14. Mergers & Acquisitions
4. Market Segmentation – By Technology
4.2. Europe Polymerase Chain Reaction in Molecular Diagnostics Market, 2013–2023 (US$ Mn)
4.3. Europe Hybridization (ISH and FISH) in Molecular Diagnostics Market, 2013–2023 (US$ Mn)
4.4. Europe Mass Spectrometry in Molecular Diagnostics Market, 2013–2023 (US$ Mn)
4.5. Europe Transcription Mediated Amplification (TMA) in Market, 2013–2023 (US$ Mn)
4.6. Europe Next Generation Sequencing in Market, 2013–2023 (US$ Mn)
4.7. Europe Biochips and Microfluidics in Market, 2013–2023 (US$ Mn)
4.8. Europe Other Technologies in Market, 2013–2023 (US$ Mn)
5. Market Segmentation – By Application
5.2. Europe Molecular Diagnostics Market for Oncology, 2013–2023 (US$ Mn)
5.3. Europe Market for Infectious Disease Testing, 2013–2023 (US$ Mn)
5.3.1. Europe Market for Virology, 2013–2023 (US$ Mn)
5.3.2. Europe Market for Bacteriology, 2013–2023 (US$ Mn)
5.4. Europe Molecular Diagnostics Market for Genomics, 2013–2023 (US$ Mn)
5.5. Europe Market for Blood Screening, 2013–2023 (US$ Mn)
5.6. Europe Market for Women’s Health, 2013–2023 (US$ Mn)
5.7. Europe Market for Microbiology, 2013–2023 (US$ Mn)
5.8. Europe Market for Prenatal and Newborn Screening, 2013–2023 (US$ Mn)
6. Europe Molecular Diagnostics Market - Regional Analysis
6.1. Northern Europe Market, 2013–2023 (US$ Mn)
6.2. Eastern Europe Molecular Diagnostics Market, 2013–2023 (US$ Mn)
6.3. Western Europe Market, 2013–2023 (US$ Mn)
6.4. Southern Europe Molecular Diagnostics Market, 2013–2023 (US$ Mn)
6.5. Rest of Europe Market, 2013–2023 (US$ Mn)
7. Current Trend and Historical Snapshot
8. Company Profiles
8.1. Abbott Laboratories
8.2. Agilent Technologies, Inc.
8.3. Alere, Inc.
8.4. Affymetrix, Inc.
8.5. bioMérieux SA
8.6. Bio-Rad Laboratories, Inc.
8.7. Cepheid, Inc.
8.8. Danaher Corporation
8.9. F. Hoffmann-La Roche Ltd.
8.10. Hologic, Inc.
8.11. Meridian Bioscience, Inc.
8.12. PerkinElmer, Inc.
8.13. Randox Laboratories, Ltd.
8.14. QIAGEN N.V.
8.15. Siemens AG
8.16. Thermo Fisher Scientific, Inc.
This report on the molecular diagnostics market studies the current and future prospects of the market in Europe. Growing incidences of chronic infectious diseases such as tuberculosis, HIV/AIDS, diarrhea, pneumonia, in addition to increasing geriatric population, and rising number of biotechnology companies is expected to accentuate the growth of this market in Europe. The Europe molecular diagnostics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the market with respect to market segments based on technology, application and their geographic analysis.
Based on technology, the molecular diagnostics market in Europe has been segmented into seven major categories: polymerase chain reaction, hybridization (ISH AND FISH), mass spectrometry, transcription mediated amplification (TMA), next generation sequencing, biochips and microfluidics, others which includes nanotechnology and proteomics. Likewise, on the basis of application, the Europe market has been segmented into oncology, infectious disease testing, genomics, blood screening, women's health, microbiology, and prenatal and newborn screening. Infectious disease testing has been segmented into two major categories, namely, virology and bacteriology. Virology segment includes human immunodeficiency virus (HIV) testing, human parainfluenza virus (1, 2, 3, 4) testing, human respiratory syncytial virus (A, B) testing, human papillomavirus (HPV) testing, human rhinovirus A/B testing, hepatitis C virus (HCV) testing, and others which includes human adenovirus (A/B/C/D/E), influenza (A, B), etc. Bacteriology includes hospital acquired infection (HAI) testing, chlamydophila pneumonia testing, chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) testing, staphylococcus aureus testing (MRSA), and others which includes haemophilus influenza, mycoplasma pneumonia, etc. The market segments have been extensively analyzed based on usefulness, adoption, efficacy, revenue, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2013 to 2023. The molecular diagnostics market report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year. A brief patient pool analysis by infectious disease, cancer and cardiovascular disease have also been discussed in the Europe molecular diagnostics report.
Geographically, the molecular diagnostics market in Europe has been categorized into five major regions: Northern Europe, Eastern Europe, Western Europe, Southern Europe, and Rest of Europe. The market size and forecast for each of these regions has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions. A detailed qualitative analysis of factors responsible for driving and restraining the growth of the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s Five Forces analysis, ADL matrix, growth share matrix, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the Europe market.
Current and future trends has also been provided for new entrants as well as existing market players to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the Europe molecular diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN N.V., Hologic, Inc., Cepheid, Inc., Siemens AG, Alere. Inc., BioMerieux, Bio-Rad Laboratories, PerkinElmer, Inc., Thermo Fisher Scientific, Inc., and others.
The Europe molecular diagnostics market is segmented as given below:
- Polymerase Chain Reaction
- Hybridization (ISH and FISH)
- Mass Spectrometry
- Transcription Mediated Amplification (TMA)
- Next Generation Sequencing
- Biochips and Microfluidics
- Others (Nanotechnology and Proteomic)
- Infectious Disease Testing
- Blood Screening
- Women's Health
- Prenatal and Newborn Screening
Europe Molecular Diagnostics Drugs Market, by Major Region and Countries
- Northern Europe
- United Kingdom
- Rest of Northern Europe (Denmark, Finland)
- Eastern Europe
- Czech Republic
- Rest of Eastern Europe (Hungary, Romania)
- Western Europe
- Rest of Western Europe (Netherlands, Belgium)
- Southern Europe
- Rest of Southern Europe (Greece, Switzerland)
- Rest of Europe